XHKG9960
Market cap139mUSD
Jan 02, Last price
1.15HKD
1D
-2.54%
1Q
-17.27%
IPO
-85.98%
Name
Kindstar Globalgene Technology Inc
Chart & Performance
P/E
24.72
P/S
1.06
EPS
0.04
Div Yield, %
0.00%
Shrs. gr., 5y
1.40%
Rev. gr., 5y
6.49%
Revenues
967m
-30.24%
Net income
41m
-45.29%
CFO
-15m
L
Dividend
Jun 07, 20240.0284 HKD/sh
Earnings
Mar 25, 2025
Profile
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 967,260 -30.24% | 1,386,591 48.99% | ||||
Cost of revenue | 1,034,875 | 1,325,730 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (67,615) | 60,861 | ||||
NOPBT Margin | 4.39% | |||||
Operating Taxes | 6,875 | 5,832 | ||||
Tax Rate | 9.58% | |||||
NOPAT | (74,490) | 55,029 | ||||
Net income | 41,286 -45.29% | 75,457 -105.19% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (28,010) | (80,350) | ||||
BB yield | 1.72% | 3.43% | ||||
| Debt | ||||||
Debt current | 165,032 | 190,998 | ||||
Long-term debt | 70,644 | 28,724 | ||||
Deferred revenue | 1,201 | 1,199 | ||||
Other long-term liabilities | 1,199 | |||||
Net debt | (1,789,573) | (908,921) | ||||
| Cash flow | ||||||
Cash from operating activities | (14,780) | 21,407 | ||||
CAPEX | (168,758) | (124,309) | ||||
Cash from investing activities | 854,922 | (1,345,153) | ||||
Cash from financing activities | (82,827) | 97,644 | ||||
FCF | (141,584) | (31,093) | ||||
| Balance | ||||||
Cash | 2,025,249 | 2,001,392 | ||||
Long term investments | (872,749) | |||||
Excess cash | 1,976,886 | 1,059,313 | ||||
Stockholders' equity | (3,236,818) | (3,196,665) | ||||
Invested Capital | 6,327,288 | 6,251,074 | ||||
ROIC | 0.89% | |||||
ROCE | 1.99% | |||||
| EV | ||||||
Common stock shares outstanding | 970,756 | 817,963 | ||||
Price | 1.68 -41.26% | 2.86 -50.00% | ||||
Market cap | 1,630,870 -30.29% | 2,339,375 -17.48% | ||||
EV | (135,714) | 1,457,665 | ||||
EBITDA | 7,410 | 125,749 | ||||
EV/EBITDA | 11.59 | |||||
Interest | 8,034 | 2,517 | ||||
Interest/NOPBT | 4.14% | |||||